Novo Nordisk Surpasses Johnson & Johnson in Market Cap, Becomes Europe's Most Valuable Company
Johnson & Johnson
Medical Device R&D and Manufacturer
Author | Chen Gongzi
Source | PharmTimes Official Account
On September 4, 2023, Novo Nordisk announced that the semaglutide weight-loss injection (Wegovy) had been approved for marketing in the UK.
Affected by recent positive news, Novo Nordisk's stock price rose nearly 2% after closing last Friday, with a market value reaching $423.646 billion.
On the other hand, after experiencing a two-week pullback in stock price, Johnson & Johnson's market value dropped to $417.083 billion. Novo Nordisk's market value officially surpassed that of Johnson & Johnson, making it the second most valuable pharmaceutical company globally.
Of course, there is still a significant gap before the next big step. As the world's largest pharmaceutical company by market value, Eli Lilly has been standing "high and lonely" above $500 billion for quite some time. It currently leads Novo Nordisk by $105.2 billion in market value, which is approximately equivalent to 4.76 BeiGene.
However, Novo Nordisk's market value doesn't necessarily have to be viewed solely from the perspective of pharmaceutical companies. Within the entire European business circle, Novo Nordisk has also surpassed the luxury goods company LVMH with this slight increase, becoming the "King of the European Market."
Source: LV Official Website
Relying solely on the field of metabolic diseases, Novo Nordisk's market value has surpassed the combined total of Merck & Co. and Bristol-Myers Squibb (BMS), achieving another level of GLP-1 > PD-1. The rise of the metabolic field is now unstoppable.
Novo Nordisk is also willing to share its experience and accumulation in the metabolic field with Chinese enterprises.
